Research Paper Volume 13, Issue 5 pp 6945—6956

Silencing of miR-483-5p alleviates postmenopausal osteoporosis by targeting SATB2 and PI3K/AKT pathway

Expressions of miR-483-5p and SATB2 in clinical samples. (A) Expressions of miR-483-5p in postmenopausal patients with or without osteoporosis. (B) Expressions of SATB2 in postmenopausal patients with or without osteoporosis. (C) Pearson correlation analysis of miR-483-5p expression and SATB2 in osteoporosis samples. (D) Pearson correlation analysis of miR-483-5p expression and SATB2 in control samples. Data were presented as mean ± SD.

Figure 1. Expressions of miR-483-5p and SATB2 in clinical samples. (A) Expressions of miR-483-5p in postmenopausal patients with or without osteoporosis. (B) Expressions of SATB2 in postmenopausal patients with or without osteoporosis. (C) Pearson correlation analysis of miR-483-5p expression and SATB2 in osteoporosis samples. (D) Pearson correlation analysis of miR-483-5p expression and SATB2 in control samples. Data were presented as mean ± SD.